In this episode of The Biotech Startups Podcast, we dive into how Nalu Bio CEO and co-founder Caitlyn Krebs is harnessing AI and the largely untapped endocannabinoid system (ECS) to build the first nonhormonal therapeutic for the two hundred million women living with endometriosis, while running an ultra-lean company with no lab, no university royalties, and a fully outsourced CRO/CMO model. She explains why CB1 and CB2 GPCRs are among pharma’s most druggable targets, how Nalu’s platform has sped drug development by 5x while doubling phase one success rates, and why the ECS may be medicine’s most overlooked frontier amid a women’s health landscape still dominated by opioids, chemical menopause, and invasive surgery.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related